BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA).
BriaCell Therapeutics is a biotechnology company based in Canada, while Sapientia is a US-based biotechnology company.
The acquisition will enable BriaCell to expand its drug discovery capabilities and broaden its pipeline.
Miltenyi Biotec subsidiary Lentigen Technology has announced the acquisition of personalised chimeric antigen receptor (CAR) T-cell therapy developer, Living Pharma.
The acquisition will enable Lentigen to progress the development of its CAR T-cell therapies.
See Also:
Both the target and the acquirer companies are based in the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData